VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
"Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer ...
HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in ...
As 2025 draws to a close, I would like to take this opportunity to look back on the year's key milestones and look to the opportunities ahead. Before diving into the detail, I would like to take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results